« All Events

Next Generation Add-On Treatment Of Inattention In ADHD: A Discussion Regarding A New Prescription Digital Therapeutic

December 14, 2022

OPEN MINDS Welcomes You To A Discussion With Akili

December 14, 2022 | 1:00 – 2:00 p.m. ET

The ongoing cognitive health crisis continues to be a clinical and economic burden in the United States. Millions of people do not receive adequate treatment for cognitive impairment. For example, research has shown that the inattention and focusing difficulty seen in people with ADHD contribute to its classification as a cognitive impairment, but a general lack of awareness of these issues leads some to see ADHD as purely behavioral. This misappropriation has a negative effect on over 16 million people who have been diagnosed with ADHD in the United States, including over 6 million children. Although traditional ADHD management combines medications and psychosocial services, in many cases these treatments alone do not sufficiently manage ADHD symptoms. There is a need for a novel approach to treating ADHD that can complement a multimodal treatment plan.

Everyone deserves to have access to new and innovative treatments that address gaps in the current treatment landscape. But where do PDTx fit within the ADHD treatment protocol? How do they elevate the standard of care in ADHD? This session will highlight the role of PDTx in the management of ADHD with a focus on gaps in the current standard of care and strategies to navigate the access landscape for PDTx.

Learning Objectives: Upon completion of this discussion, participants should be able to:

  1. Understand the cognitive health crisis that exists today and the promise of PDTx to provide a solution
  2. Discuss ADHD and the gaps within the current standard of care
  3. Discuss the place in therapy and treatment protocol of current PDTx to treat ADHD
  4. Understand strategies to help overcome the challenges of PDTx coverage, including formulary decision making, coding, billing, and reimbursement

Details

Date:
December 14
Time:
1:00 pm - 2:00 pm
Event Categories:
,

Featured Speakers

Greg Lyles, Vice President Market Access, Akili Interactive Labs, Inc.

Andrey Ostrovsky, Managing Partner, Social Innovation Ventures; Former CMO of US Medicaid Program

Kelcey S., Caregiver

Paul Duck, Senior Associate, OPEN MINDS


Registration for this executive web briefing is free.

Unable to attend? Still register! At the conclusion of the event, all registrants will receive a recorded copy of the executive web briefing and presentation slides.

Register
Event Sponsored By:

About Akili

Akili is pioneering the development of cognitive treatments through game-changing technologies. Our approach of leveraging technologies designed to directly target the brain establishes a new category of medicine – medicine that is validated through clinical trials like a drug or medical device, but experienced like entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s products are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com.

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!